All articles tagged: Non-Hodgkin lymphoma, unspecified, unspecified site (C85.90)

Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum

First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online May 13 in Clinical Lymphoma, Myeloma & Leukemia.Nilanjan Ghosh, M.D., Ph.D., from the Levine Cancer Institute in Charlotte, North Carolina, and colleagues condu

For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.Christopher Melani, M.D., fro

Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine.Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016.

University of Wisconsin–Madison researchers have uncovered a critical process driving resistance in certain types of lymphoma, offering hope for patients who become resistant to standard treatments. The study focused on understanding why some patients with B-cell malignancies, such as mantle cell lymphoma and diffuse large B-cell lymphoma, develop resistance to Bruton tyrosine kinase inhibitors (B

The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif

Toby Keith, a beloved figure in the country music scene, has recently passed away, leaving fans and the music industry in mourning. However, his death has also brought attention to an important health issue: stomach cancer. In this article, we’ll delve into the details of stomach cancer, Toby Keith’s battle with the disease, and what can be learned from his experience.

The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and

Exposure to traffic-related air pollution may be associated with an increased risk for childhood leukemia, according to a study published in the August issue of Environment International.Christian Kreis, Ph.D., from the University of Bern in Switzerland, and colleagues investigated the association between traffic-related air pollution

Increasing body mass index (BMI) at age 18 years is associated with development of subsequent site-specific cancers in men, according to a study published online Nov. 6 in Obesity.Aron Onerup, M.D., Ph.D., from the University of Gothenburg in Sweden, and colleagues examined BMI at age 18 years and incident site-specific cancer (

For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual

The FDA is investigating the risk of secondary cancers in patients treated with CAR-T therapies, used for certain cancers like leukemia and lymphoma. Nineteen cases of T-cell malignancies have been reported following these treatments. While CAR-T therapies are beneficial, there's growing concern about their potential risks, including serious T-cell malignancies. The FDA advises lifelong monitoring